Straits Times Index
3,310.96 +10.96 (+0.33%) Nikkei
38,587.35 -45.67 (-0.12%) Hang Seng
18,075.52 -259.80 (-1.42%) FTSE 100
8,272.46 +67.35 (+0.82%) Bitcoin USD
64,620.56 -878.55 (-1.34%) CMC Crypto 200
1,354.01 -6.32 (-0.46%)
VSTM Dec 2024 2.000 call
| Previous close | 1.7400 |
| Open | 1.6000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.00 |
| Expiry date | 2024-12-20 |
| Day's range | 1.6000 - 1.7400 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksVerastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
BenzingaWhat's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Thursday, Verastem Oncology (NASDAQ:VSTM) announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer. The initial interim results will be presented at the upcoming American Society of Clinical Oncology Annual Meeting. As of May 14, patients receiving the combination of avutometinib and defactinib with g
Business WireVerastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
BOSTON, May 24, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of the combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, for adult patients with recurrent KRAS mutant (KRAS mt) low-grade serous ovarian cancer
